GP96 C‐terminal improves Her2/neu DNA vaccine

Abstract

The C-terminal of GP96 has potent adjuvant activity in eliciting a significant immune response when fused with Her2/neu. It may be used as molecular adjuvant along with other tumor or bacterial/viral antigens.

Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent

“…In this article, the result on the efficiency of C-terminally fusion of gp96 Cterminal to TM+ECD of rat Her2/neu DNA vaccine is presented. It is noteworthy to remind that this study was conducted at the same time of the previous report (Pakravan et al 2010a). The results of N-terminally fusion of gp96 Cterminal to TM+ECD of rat Her2/neu were published previously (Pakravan et al 2010a) and statistical analysis with C-terminally fusion of gp96 C-terminal to TM+ECD of rat Her2/neu have been mentioned here for comparison.…”

“…NM_003299) was cloned into pHer2, downstream of Her2/neu (pHer2/CT). Preparation of pCT/Her2 was described previously (Pakravan et al 2010a). The expression of each construct was evaluated by cloning of green fluorescent gene at the end of gene, as described previously (Pakravan et al 2010c).…”

“…We previously (Pakravan et al 2010a) demonstrated that fusion, but not co-administration, of gp96 C-terminal domain to TM+ECD of rat Her2/neu led to better inhibition of tumor growth. It prompted us to present results indicating increased efficiency of TM+ECD of rat Her2/neu DNA vaccine, when fused C-terminally to gp96 C-terminal domain.…”

A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers

“…Some studies have shown the adjuvant activity of the N-/C-terminal domains of gp96 in DNA or protein vaccine strategies. For instance, fusion of the C-terminal domain to Her2/neu inhibited the tumor growth (Pakravan et al, 2010). Moreover, the N-terminal domain has also potent adjuvant activity toward hepatitis B surface antigen (Yan et al, 2007).…”

Mini-chaperones

“…Therefore, the C-terminal of gp96 can be used as molecular adjuvant along with other tumor/ bacterial/viral antigens for improving vaccine potency. 52 Furthermore, our research group applied two strategies including linkage of immune-stimulatory molecules (N-terminal of gp96), accompanied with PEI600-Tat as non-viral gene delivery system to evaluate DNA vaccine efficacy against HPV infections. It was found that immunization with E7-NT (gp96) fusion gene led to increase IFN-γ level as compared with E7 alone.…”